| 2026-02-04 |
详情>>
内部人交易：
Levy Jordan等共交易5笔
|
| 2025-10-24 |
详情>>
股本变动：
变动后总股本31006.13万股
|
| 2025-10-24 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.48美元,归母净利润-5.03亿美元,同比去年增长52.09%
|
| 2025-09-29 |
股东大会：
将于2025-10-30召开股东大会
会议内容 ▼▲
- 1.Core Scientific’s proposal to adopt the Merger Agreement (the “Merger Agreement Proposal”).
2.Core Scientific’s proposal to approve, on a non-binding advisory basis, the compensation that may be paid or become payable to Core Scientific’s named executive officers that is based on or otherwise related to the Merger (the “Advisory Compensation Proposal”).
3.To transact any other business that properly comes before the Special Meeting, including any postponement or adjournment thereof.
|
| 2025-08-08 |
详情>>
业绩披露：
2025年中报每股收益-0.21美元,归母净利润-3.56亿美元,同比去年增长40.07%
|
| 2025-08-08 |
财报披露：
美东时间 2025-08-08 盘后发布财报
|
| 2025-06-27 |
复牌提示：
2025-06-26 12:27:46 停牌，复牌日期 2025-06-26 12:37:46
|
| 2025-05-07 |
详情>>
业绩披露：
2025年一季报每股收益1.44美元,归母净利润5.81亿美元,同比去年增长175.61%
|
| 2025-03-28 |
股东大会：
将于2025-05-12召开股东大会
会议内容 ▼▲
- 1.To elect the Board of Directors’ nominee for director identified in the attached proxy statement to hold office until the 2028 Annual Meeting of Stockholders (if Proposal 4 is not approved), or until the 2026 Annual Meeting of Stockholders (if Proposal 4 is approved).
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement.
3.To indicate, on a non-binding, advisory basis, the preferred frequency of stockholder advisory votes to approve the compensation of our named executive officers.
4.To approve an amendment of the Company’s Third Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to declassify the Board of Directors.
5.To approve an amendment of the Company’s Certificate of Incorporation to eliminate the supermajority vote requirement for stockholders to amend certain provisions of our Certificate of Incorporation.
6.To approve an amendment of the Company’s Certificate of Incorporation to eliminate certain consent rights provided to our creditors in connection with the Company’s emergence from bankruptcy and make other non-substantive and conforming changes.
7.To approve our Amended and Restated 2024 Stock Incentive Plan.
8.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
9.To approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 4, 5, and 6.
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益-4.39美元,归母净利润-13.15亿美元,同比去年增长-433.5%
|
| 2025-02-27 |
详情>>
业绩披露：
2022年年报每股收益-6.3美元,归母净利润-21.46亿美元,同比去年增长-4636.52%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-3.71美元,归母净利润-10.49亿美元,同比去年增长-1966.12%
|
| 2024-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.13美元,归母净利润-5079.4万美元,同比去年增长97.03%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益-2.87美元,归母净利润-5.94亿美元,同比去年增长-6058.84%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益0.91美元,归母净利润2.11亿美元,同比去年增长54401.80%
|
| 2024-03-13 |
详情>>
业绩披露：
2023年年报每股收益-0.65美元,归母净利润-2.46亿美元,同比去年增长88.52%
|
| 2022-04-08 |
股东大会：
将于2022-05-11召开股东大会
会议内容 ▼▲
- 1.To elect the nominees to the Board of Directors (the “Board”) named in the accompanying proxy statement (the “Proxy Statement”), Michael Levitt, Darin Feinstein, Jarvis Hollingsworth, Matt Minnis, Stacie Olivares and Kneeland Youngblood, to hold office until the 2023 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
2.To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.
3.To conduct any other business properly brought before the Annual Meeting.
|
| 2022-01-03 |
股东大会：
将于2022-01-19召开股东大会
会议内容 ▼▲
- 1.To consider and vote upon a proposal to approve the Agreement and Plan of Merger and Reorganization, dated as of July 20, 2021 (as amended on October 1, 2021, and as it may be further amended and/or restated from time to time, the “merger agreement”), by and among XPDI, XPDI Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of XPDI, and Core Scientific Holding Co., a Delaware corporation (“Core Scientific”), and the transactions contemplated thereby (collectively, the “merger”). Copies of the merger agreement, the First Amendment to Agreement and Plan of Merger and Reorganization, dated as of October 1, 2021, the Second Amendment to Agreement and Plan of Merger and Reorganization, dated as of December 29, 2021, are attached to the accompanying proxy statement/prospectus as Annex A, Annex B, and Annex K respectively (Proposal No. 1);
2.To consider and vote upon a proposal to adopt the proposed second amended and restated certificate of incorporation (the “Proposed Charter”) in the form attached to the accompanying proxy statement/prospectus as Annex C and the proposed second amended and restated bylaws (the “Proposed Bylaws”) in the form attached to the accompanying proxy statement/prospectus as Annex D, of XPDI after the merger (referred to herein as “New Core”) (Proposal No. 2);
3.To consider and vote upon, on a non-binding advisory basis, certain governance provisions in the Proposed Charter, presented separately in accordance with the requirements of the Securities and Exchange Commission (“SEC”):(a)To increase the total number of shares of all classes of authorized capital stock from (i) 551,000,000, consisting of (a) 550,000,000 shares of common stock, including (1) 500,000,000 shares of Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), and (2) 50,000,000 shares of Class B common stock, par value $0.0001 per share (the “Class B Common Stock” and, together with the Class A Common Stock, the “XPDI common stock”), and (b) 1,000,000 shares of preferred stock, par value $0.0001 per share, to (ii) 12,000,000,000, consisting of (A) 10,000,000,000 shares of common stock, par value $0.0001 per share, and (B) 2,000,000,000 shares of preferred stock, par value $0.0001 per share (Proposal No. 3A);(b)To provide that any amendment to the Proposed Bylaws will require the approval of either New Core’s board of directors or the holders of at least 66 2/3% of the voting power of New Core’s then-outstanding shares of capital stock entitled to vote generally in an election of directors, voting together as a single class (Proposal No. 3B);(c)To provide that any amendment to certain provisions of the Proposed Charter will require the approval of the holders of at least 66 2/3% of the voting power of New Core’s then-outstanding shares of capital stock entitled to vote generally in an election of directors, voting together as a single class (Proposal No. 3C);
4.To consider and vote upon a proposal to approve, for purposes of complying with applicable listing rules of the Nasdaq: (i) the issuance of shares of New Core common stock pursuant to the merger agreement and (ii) the related change of control of XPDI that will occur in connection with consummation of the merger and the other transactions contemplated by the merger agreement (Proposal No. 4);
5.To consider and vote upon a proposal to approve and adopt the Core Scientific, Inc. 2021 Equity Incentive Plan (the “2021 Plan”) in substantially the form attached to the accompanying proxy statement/prospectus as Annex I (Proposal No. 5);
6.To consider and vote upon a proposal to approve and adopt the Core Scientific, Inc. 2021 Employee Stock Purchase Plan (the “ESPP”) in substantially the form attached to the accompanying proxy statement/prospectus as Annex J (Proposal No. 6);
7.To consider and vote upon a proposal to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Special Meeting, there are not sufficient votes to approve the Business Combination Proposal, the Charter Proposal, the Governance Proposals, the Nasdaq Proposal, the Incentive Plan Proposal or the ESPP Proposal (Proposal No. 7).
|